-53%

est. 2Y upside i

HealthcareSeries A

Rank

#3708

Sector

Biotechnology / Pharmaceuticals

Est. Liquidity

~2Y

Data Quality

Data: Medium

The expected upside over 2 years is -53.1%, indicating the equity grant is likely to be underwater.

Last updated: July 3, 2026

Bull (20%)+23%

Pipeline momentum, especially potential BBP-418 approval, sustains a high revenue multiple of 50x on projected $401.7M revenue, yielding 22.6% net upside after 15% dilution.

Base (30%)-46%

Multiple contracts to 25x as revenue grows to $401.7M but fails to justify current $14.6B valuation, resulting in a 46.2% loss after dilution.

Bear (50%)-88%

Intense competition from Pfizer and Alnylam compresses the multiple to 10x, with revenue missing expectations, leading to an 87.5% loss after dilution.

Est. time to liquidity~2.0 years

Preference Stack Risk

low

Funding Intensity

640%

The latest $933.9M preferred round implies a ~6.4% preference overhang; total funding is unknown but likely moderate.

Dilution Risk

moderate

Assuming 15% dilution from option pools or future capital raises within 2 years.

Secondary Liquidity

none

No secondary market activity reported; liquidity expected via IPO or acquisition.

Other — 70 roles

View all 70 open roles at BridgeBio →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on BridgeBio's data — designed to show you've done your homework.

  • 1

    “How does BridgeBio's hub-and-spoke model de-risk pipeline compared to a traditional biotech?”

  • 2

    “With Pfizer and Alnylam competing in TTR amyloidosis, what is the go-to-market strategy to differentiate Attruby?”

  • 3

    “Given the current $14.6B valuation, how do you view the equity's potential appreciation over your vesting schedule, and what liquidity events are realistic?”

Community

Valuation Sentiment

Our model estimates -53% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.